Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Chris Kalberg"'
Autor:
Edward Kerwin, Dmitry V Galkin, John H. Riley, Chang-Qing Zhu, Chris Kalberg, Alison Church, William A. Fahy
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Introduction Patients with COPD who remain symptomatic on long-acting bronchodilator monotherapy may benefit from step-up therapy to a long-acting bronchodilator combination. This study evaluated the efficacy and safety of umeclidinium (UMEC)/vilante
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebcea37b3a02413c7d18c0f0ca663f12
https://doi.org/10.2147/copd.s119032
https://doi.org/10.2147/copd.s119032
Publikováno v:
ERJ Open Research, Vol 4, Iss 1 (2018)
ERJ Open Research
ERJ Open Research
This multicentre, randomised, double-blind, placebo-controlled, two-period crossover study assessed the effect of umeclidinium/vilanterol (UMEC/VI) on exercise capacity in patients with chronic obstructive pulmonary disease (COPD) using the endurance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6645513e094817ecf11274a4a1f99a3
http://openres.ersjournals.com/content/4/1/00073-2017.full
http://openres.ersjournals.com/content/4/1/00073-2017.full
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 31:85-91
Background The bronchodilator response to short-acting β2-agonist and short-acting muscarinic antagonist monotherapies varies on a day-to-day basis within individual patients. The objective of this study was to compare daily variation in bronchodila
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb62d253ba0bdb3f9eb4e3a52b89519
https://doi.org/10.1016/j.pupt.2014.08.010
https://doi.org/10.1016/j.pupt.2014.08.010
Autor:
Maggie Tabberer, Bartolome R. Celli, Glenn Crater, Alison Church, Rashmi Mehta, Chris Kalberg, Sally Kilbride
Publikováno v:
Chest. 145:981-991
Background Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the efficacy and safety of once-daily umeclidinium bromide (UMEC)/vilanterol (VI) 125/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60a637f4a01f6fef42f1a52dfbadccc5
https://doi.org/10.1378/chest.13-1579
https://doi.org/10.1378/chest.13-1579
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Introduction In patients with moderate-to-very severe COPD, umeclidinium/vilanterol (UMEC/VI) reduced clinically important deteriorations (CID) vs tiotropium (TIO) over 24 weeks (Singh D, et al. AJRCCM 2015;191:A5760). Here we investigate the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43e23896f4411633fb396d655bee5beb
https://doi.org/10.1183/13993003.congress-2016.pa980
https://doi.org/10.1183/13993003.congress-2016.pa980
Autor:
William A. Fahy, Dmitry V Galkin, Alison Church, Chang-Qing Zhu, Chris Kalberg, A. Compagnon, E. Kerwin
Publikováno v:
Revue des Maladies Respiratoires. 34:A172-A173
Introduction L’association d’un anticholinergique et d’un β2 agoniste de longue duree d’action (LAMA et LABA) en escalade therapeutique pourrait ameliorer les resultats cliniques chez les patients BPCO non suffisamment controles par un LAMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a7608b3d7b480c0dcdc0ceb05e7a4a7
https://doi.org/10.1016/j.rmr.2016.10.408
https://doi.org/10.1016/j.rmr.2016.10.408
Autor:
Julie C. Yates, Chris Kalberg, Donald H. Horstman, Amanda Emmett, Nicola A. Hanania, Katharine Knobil
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 18:19-22
Long-acting beta(2)-agonists (LABAs) are recommended in the management of patients with chronic obstructive pulmonary disease (COPD). Previous studies have demonstrated that the LABA, salmeterol, improves lung function, symptoms and quality of life i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3a9e5733938b330cddffdf73268ac7
https://doi.org/10.1016/j.pupt.2004.07.005
https://doi.org/10.1016/j.pupt.2004.07.005
Autor:
Maria D. Van Kerkhove, Jordana K. Schmier, Michael L. Watkins, Michael T. Halpern, Chris Kalberg
Publikováno v:
Annals of Allergy, Asthma & Immunology. 92:201-207
Background The impact of long-term inhaled corticosteroid (ICS) therapy on bone mineral density (BMD) is poorly understood. Objective To evaluate the impact of long-term ICS use on BMD. Methods Random-effects meta-analysis. Published and unpublished
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dec0e668048f0e4c164d6bcca1c6ed70
https://doi.org/10.1016/s1081-1206(10)61548-7
https://doi.org/10.1016/s1081-1206(10)61548-7
Autor:
Kathleen Rickard, Eli O. Meltzer, Stacey Goode-Sellerso, Bruce Friedman, Lisa D. Edwards, Sharon Srebro, Richard F. Lockey, Chris Kalberg
Publikováno v:
Mayo Clinic Proceedings. 77:437-445
To compare the long-term effects of an inhaled corticosteroid with those of a leukotriene modifier on measures of clinical efficacy, subject preference, and safety in patients with persistent asthma.Between November 17, 1998, and May 26, 2000, we con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f7b8b9dc268339b32b6c2ed4862a993
https://doi.org/10.4065/77.5.437
https://doi.org/10.4065/77.5.437
Publikováno v:
Revue des Maladies Respiratoires. 34:A150
Introduction Les patients BPCO qui restent symptomatiques apres traitement par un anticholinergique longue duree d’action en monotherapie pourraient beneficier d’une escalade therapeutique par l’association d’un anticholinergique et d’un β
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af9d970d364f31a1a142957b24cf0f6b
https://doi.org/10.1016/j.rmr.2016.10.357
https://doi.org/10.1016/j.rmr.2016.10.357